ESBRIET (pirfenidone) capsules and film-coated tablets, for oral use Initial U.S. Approval: 2014

Category: .

ESBRIET (pirfenidone) capsules and film-coated tablets, for oral use Initial U.S. Approval: 2014

INDICATIONS AND USAGE
ESBRIET is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
DOSAGE FORMS & STRENGTHS
• Capsules: 267 mg
• Tablets: 267 mg, 801 mg
Manufactured By: Genentech
Prescribing Information URL: Click Here

Access to ESBRIET ® (pirfenidone) capsules and film-coated tablets: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Pirfenidone is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II.
It was first approved in Japan for the treatment of patients with idiopathic pulmonary fibrosis after clinical trials, under the trade name of Pirespa by Shionogi, in 2008. It was approved for use in the European Union in 2011, in Canada in 2012, and in the United States in October 2014. There is also a topical form created for the treatment of abnormal wound healing processes.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.